STAF42 inhibitors represent a novel class of chemical compounds that target the activity of the STAF42 protein, which plays a critical role in intracellular signaling pathways. These inhibitors are characterized by their ability to selectively bind to the active site or regulatory domains of the STAF42 protein, thereby modulating its function within various biochemical networks. STAF42, being a key regulator in processes such as gene expression, signal transduction, and protein-protein interactions, is often associated with cellular mechanisms that control growth and differentiation. Inhibition of STAF42 function can lead to alterations in these cellular pathways, ultimately affecting the overall balance of cellular activities. The design of STAF42 inhibitors typically involves the identification of small molecules that can efficiently interfere with the protein's conformational flexibility or substrate binding sites, rendering it inactive or significantly reducing its activity.
Chemically, STAF42 inhibitors often possess specific structural motifs that allow for tight and selective binding. These motifs can include heterocyclic rings, hydrophobic cores, or polar functional groups that are capable of forming hydrogen bonds with key residues in the STAF42 binding pocket. Researchers working on this class of inhibitors utilize a variety of synthetic strategies, including fragment-based drug discovery (FBDD), high-throughput screening, and structure-activity relationship (SAR) studies, to optimize binding affinity and selectivity. Structural biology techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are frequently employed to elucidate the molecular interactions between STAF42 inhibitors and their target protein, aiding in the rational design of more potent compounds. Moreover, the use of computational modeling and in silico docking approaches has become an integral part of the development pipeline for these inhibitors, allowing scientists to predict and refine their binding modes with higher precision.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR pathway which can be a common signaling route for several proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor, affecting downstream signaling proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially affecting related pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, affecting MAPK/ERK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, affecting the JNK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Broad spectrum kinase inhibitor. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Inhibits NF-kB activation. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
Inhibits IKK-2, affecting NF-kB pathway. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
JAK2 inhibitor, affecting JAK-STAT signaling. | ||||||